Evidence map›Paper›PMID 31233632›Full record

ReviewJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2019

Gaucher Disease in Bone: From Pathophysiology to Practice.

Derralynn Hughes, Peter Mikosch, Nadia Belmatoug, Francesca Carubbi, TimothyM Cox, Ozlem Goker-Alpan, Andreas Kindmark, PramodK Mistry, Ludger Poll, Neal Weinreb and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 198 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. [Bone infarctions-from pathophysiology to imaging].Radiologie (Heidelberg, Germany) · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 7 countries.

Derralynn HughesRoyal Free London NHS Foundation Trust and University College London, UK.
Peter MikoschDepartment of Internal Medicine 2, Landesklinikum Mistelbach, Austria, and Medical University Vienna, Externe Lehre, Vienna, Austria.
Nadia BelmatougReferral Center for Lysosomal Diseases, Department of Internal Medicine, University Hospital Paris Nord Val de Seine, Assistance Publique-Hôpitaux de Paris, Clichy, France.
Francesca CarubbiDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, NOCSAE Hospital, AOU Modena, Italy.
TimothyM CoxDepartment of Medicine, University of Cambridge, Cambridge, UK.
Ozlem Goker-AlpanLysosomal Disorders Research and Treatment Unit, Fairfax, VA, USA.
Andreas KindmarkDepartment of Endocrinology and Diabetology, Uppsala University Hospital, Uppsala, Sweden.
PramodK MistryDepartment of Internal Medicine (Digestive Diseases), Yale University School of Medicine, New Haven, CT, USA.
Ludger PollPractice of Radiology and Nuclear Medicine Duisburg-Moers, Heinrich-Heine University Düsseldorf, Duisburg, Germany.
Neal WeinrebDepartments of Human Genetics and Medicine (Hematology), Miller School of Medicine, University of Miami, FL, USA.
Patrick DeeganLysosomal Disorders Unit, Addenbrooke's Hospital, Cambridge, UK.
Addenbrooke's Hospital · GBAssistance Publique – Hôpitaux de Paris · FRHeinrich Heine University Düsseldorf · DELysosomal and Rare Disorders Research and Treatment Center · USMedical University of Vienna · ATNational Operating Committee on Standards for Athletic Equipment · USUniversity College London · GBUniversity of Cambridge · GBUniversity of Miami · USUppsala University Hospital · SEYale University · US

Funding

Understanding the skeletal phenotype of Gaucher diseaseR01AR065932 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MISTRY, PRAMOD K, ZAIDI, MONE · 2013 to 2017
$2.6M
NIAMS NIH HHS R01 AR065932Sanofi-Genzyme
6 · The paper itself

Abstract

Gaucher disease (GD) is a rare, genetic lysosomal disorder leading to lipid accumulation and dysfunction in multiple organs. Involvement of the skeleton is one of the most prevalent aspects of GD and a major cause of pain, disability, and reduced quality of life. Uniform recommendations for contemporary evaluation and management are needed. To develop practical clinical recommendations, an international group of experienced physicians conducted a comprehensive review of 20 years' of the literature, defining terms according to pathophysiological understanding and pointing out best practice and unmet needs related to the skeletal features of this disorder. Abnormalities of bone modeling, reduced bone density, bone infarction, and plasma cell dyscrasias accompany the displacement of healthy adipocytes in adult marrow. Exposure to excess bioactive glycosphingolipids appears to affect hematopoiesis and the balance of osteoblast and osteoclast numbers and activity. Imbalance between bone formation and breakdown induces disordered trabecular and cortical bone modeling, cortical bone thinning, fragility fractures, and osteolytic lesions. Regular assessment of bone mineral density, marrow infiltration, the axial skeleton and searching for potential malignancy are recommended. MRI is valuable for monitoring skeletal involvement: It provides semiquantitative assessment of marrow infiltration and the degree of bone infarction. When MRI is not available, monitoring of painful acute bone crises and osteonecrosis by plain X-ray has limited value. In adult patients, we recommend DXA of the lumbar spine and left and right hips, with careful protocols designed to exclude focal disease; serial follow-up should be done using the same standardized instrument. Skeletal health may be improved by common measures, including adequate calcium and vitamin D and management of pain and orthopedic complications. Prompt initiation of specific therapy for GD is crucial to optimizing outcomes and preventing irreversible skeletal complications. Investing in safe, clinically useful, and better predictive methods for determining bone integrity and fracture risk remains a need. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Indexed as

Practice Patterns, Physicians'Bone and BonesBone DiseasesBone MarrowBone RemodelingGaucher DiseaseHumansBIOMARKERSBONE DISEASEGAUCHER DISEASEOSTEONECROSISOSTEOPOROSISRADIOLOGYTHERAPEUTICS

Identifiers

PMID31233632
PMCPMC6852006
OpenAlexW2956136291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.